Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 50
- Registration Number
- NCT05281406
- Locations
- 🇩🇪
Universitätsklinik Köln, Lung Cancer Group Cologne - Innere Medizin I, Köln, Germany
🇩🇪LMU-München Pneumologie und Thorakale Onkologie Medizinische Klinik V; Innenstadt, München, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf Hubertus Wald Tumorzentrum - UCCH II. Medizinische Klinik und Poliklinik, Hamburg, Germany
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 324
- Registration Number
- NCT05261399
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 67
- Registration Number
- NCT05228015
- Locations
- 🇦🇺
Peninsula South Eastern Haematology and Oncology Group (PASO Medical), Frankston, Victoria, Australia
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT05215951
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
- Conditions
- Stage III Lung Cancer AJCC v8Unresectable Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IVB Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Locally Advanced Lung Non-Small Cell CarcinomaStage IIIA Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05166616
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 44
- Registration Number
- NCT05163249
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT05153408
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
- Conditions
- Interventions
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 380
- Registration Number
- NCT05120349
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
- Conditions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 274
- Registration Number
- NCT05103605
- Locations
- 🇫🇷
Research Site, Villeurbanne, France
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 40
- Registration Number
- NCT05089916
- Locations
- 🇩🇪
LMU Klinikum der Universität München, München, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.